NanoViricides (NYSE American: NNVC), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has nominated a clinical drug candidate for the treatment of COVID-19. The announcement advances the company’s COVID-19 program one step closer to human clinical trials. The company is working to accelerate its drug-development program for COVID-19 treatment. NNVC’s ultimate goal is to develop the most effective medicine and to obtain regulatory approval for emergency use in the COVID-19 pandemic in the shortest timeline feasible. With that in mind, the company is aggressively working to harness the full power of its nanoviricides(R) nanomedicine platform. The clinical candidate NNVC has nominated is identified as NV-CoV-1-R and is made up of a nanoviricide found to possess broad-spectrum anti-coronavirus activity. “This is an extremely important milestone for the company,” NanoViricides president and executive chairman Anil R. Diwan stated in the press release. “We look forward to rapid development of the IND enabling core safety pharmacology studies and, thereafter, human clinical development on an accelerated timeline in these trying times of the pandemic.”
To view the full press release, visit http://nnw.fm/QorVB
About NanoViricides Inc.
NanoViricides is a development-stage company that is creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. NNVC’s lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, the company has declared a clinical0development candidate, namely NV-CoV-1-R, which encapsulates remdesivir inside NV-CoV-1, for the treatment of COVID-19. The company cannot project an exact date for filing an IND for NV-CoV-1-R because of its dependence on a number of external collaborators and consultants.
The company is now working on performing required safety pharmacology studies and completing an IND application for NV-CoV-1-R. NanoViricides believes that since remdesivir already has an emergency use approval, NV-CoV-1-R is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. NanoViricides has developed NV-CoV-1-R independently.
The company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.
The company is also developing drugs against a number of viral diseases including oral and genital herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola virus, among others. NanoViricides’s platform technology and programs are based on the TheraCour(R) nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: human immunodeficiency virus (HIV/AIDS), hepatitis B virus (“HBV”), hepatitis C virus (“HCV”), rabies, herpes simplex virus (HSV-1 and HSV-2), varicella-zoster virus (“VZV”), influenza and Asian bird flu virus, dengue viruses, Japanese encephalitis virus, West Nile virus and Ebola/Marburg viruses. The company has executed a Memorandum of Understanding with TheraCour that provides a limited license for research and development for drugs against human coronaviruses. The company also intends to obtain a full license and has begun the process for the same. The company’s technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma Inc. The company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. For more information about the company, visit www.NanoViricides.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
